Quality you can trust
Our dedication to quality is uncompromising, and covers every stage of the development, production and marketing of our medicines
Teva's extensive global operations network includes more than 25,000 employees at 80 manufacturing sites in 33 countries.
Here in Ireland, we have three main locations in the Republic of Ireland, and two in Northern Ireland.
We have a large manufacturing site in Waterford which focusses on the manufacture and development of respiratory products for supply to the United States and around 30 other global markets. It includes an onsite research and development centre.
We have a manufacturing plant in Baldoyle in Dublin which makes the over-the-counter medication Sudocrem®, first developed in 1931 and now a multi-award winning, globally recognised product sold in over 50 countries. We have a Commercial / Support office in Dundalk.
In Northern Ireland, we have manufacturing and research facilities in Coleraine and Larne.
We integrate our generics and specialty capabilities in global research and development to meet patient needs by combining drug development capabilities with devices, services and technologies.
We strive to deliver high-quality generic and specialty products to different markets - quickly and effectively. This includes highly-responsive customer service representatives, account managers and scientific and logistical support, as well as Research & Development, Quality Assurance, Regulatory Affairs, Intellectual Property and marketing personnel.
Our dedication to quality is uncompromising, and covers every stage of the development, production and marketing of our medicines. Our state-of-the-art manufacturing facilities feature the most advanced testing equipment to guarantee the quality of our products. Equipment is tested and certified, and every manufacturing process is validated.
Teva’s impeccable adherence to Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) is recognized by FDA approval of 26 of our plants, and EMA approval of 31 of our plants. Moreover, each of our pharmaceutical manufacturing facilities is inspected and approved by at least two regulatory authorities worldwide.
With a global presence, timely, reliable and cost-effective distribution is critical to our customers’ ability to provide their end consumers with safe and effective products on time. Our manufacturing network is continuously optimised so that our customers can have full confidence in our supply chain. This is enabled by high-volume, technologically-advanced distribution facilities. These facilities allow us to deliver new products swiftly and reliably. We continually review our capabilities and capacity. This ensures that we can consistently deliver best-in-class products.